A practical reference on clinical evidence: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-13 and is reviewed periodically as new material appears.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
=== Medical complications === The emplacement of a prosthetic breast presents the risks of medical complication usual to undergoing surgery, such as: an adverse reaction to anesthesia, a breast hematoma (post-operative bleeding), a seroma (fluid accumulation), and infection of the surgical wound. The medical complications of breast augmentation include: pain in the breast, altered tactile sensation, wrinkling and asymmetry of the breast hemisphere, thinning of the breast skin, impeded breastfeeding functions, and symmastia, the bread-loafing of the bust, which condition elevates the natural plane (cleavage) between the breast hemispheres. The functional complications of the prosthetic breast — capsular contracture and capsular rupture — are managed with periodic, preventative physical examinations and MRI examinations. Medical complications from the emplacement surgery and complications (scarring) from the application of tissue expanders (place-holder prosthetics) occur in approximately six to seven per cent (6–7%) of breast-augmentation patients. Statistically, twenty per cent (20%) of women with prosthetic breasts for aesthetic enhancement, and fifty per cent (50%) of women with prosthetic breasts for breast reconstruction, required the explantation of their failed breast-prostheses at the ten-year mark.
An increased risk of severe bacterial infections is due to the loss of functioning spleen tissue. These infections are typically caused by bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. Daily penicillin prophylaxis is the most commonly used treatment during childhood, with some haematologists continuing treatment indefinitely. Patients benefit from routine vaccination for S. pneumoniae. Stroke can result from blockage of blood vessels in the brain, causing numbness, confusion, or weakness, which may be long-lasting. Silent stroke causes no immediate symptoms, but is associated with damage to the brain. Silent stroke is probably five times as common as symptomatic stroke. About 10–15% of children with sickle cell disease have strokes, with silent strokes predominating in the younger patients. Cholelithiasis (gallstones) and cholecystitis may result from excessive bilirubin production and precipitation due to prolonged haemolysis. Avascular necrosis (aseptic bone necrosis) of the hip and other major joints may occur as a result of ischaemia. Priapism and infarction of the penis. Osteomyelitis (bacterial bone infection) as a result of damage to the spleen, commonly caused by either Staphylococcus aureus or species of Salmonella. Chronic kidney failure due to sickle-cell nephropathy manifests itself with hypertension, protein loss in the urine, loss of red blood cells in urine, and worsened anaemia. If it progresses to end-stage kidney failure, it carries a poor prognosis. Leg ulcers are relatively common in sickle cell disease and can be disabling.
== See also == SDF–Syrian transitional government clashes (2025–present) Turkish offensive into northeastern Syria (2024–2025) Israeli invasion of Syria (2024–present) Hezbollah–Syria clashes (2024–present) Western Syria clashes
Sources: en.wikipedia.org
=== March === 11 March – Clive Revill, actor (The Empire Strikes Back, Irma La Douce, Oliver!) (born 1930). 13 March – Brian McMahon, venereologist, army officer, medical superintendent (Wakari Hospital, Dunedin Hospital) and lecturer (University of Otago) (born 1929). 14 March – Anne Nightingale, nurse, chair of the Nursing Council (1975–1984) (born 1932). 16 March – Gordon H. Brown, art historian, gallery director (Waikato Art Gallery, Sarjeant Gallery), and artist (born 1931). 20 March – Matt Mitchell, sailor (Team New Zealand, Alinghi, Oracle Team USA) (born c. 1971). 21 March – Nick Carter, lawyer and judge, Māori Land Court judge (1989–2002) (born 1935). 22 March – Alex Wyllie, rugby union player (Canterbury, national team) and coach (Canterbury, national team, Argentina) (born 1944). 31 March Sir Roger Clifford, 7th Baronet (born 1936). Ron Jones, obstetrician and gynaecologist (National Women's Hospital, University of Auckland), whistleblower in the "Unfortunate Experiment" (born 1939).
== U == Ultradian rhythm A recurrent biological cycle that occurs more than once in 24 hours, such as stages of sleep. In neuroscience, it refers to shorter rhythms regulating hormonal release, arousal, or sleep cycles. Unconditioned response In classical conditioning, an automatic, reflexive response to an unconditioned stimulus (e.g., salivation to food). Studied in behavioral neuroscience. Unconsciousness A state in which an individual is not aware of themselves or their surroundings. Can result from head injury, anesthesia, or metabolic dysfunction. Uncus A structure on the medial surface of the temporal lobe, part of the parahippocampal gyrus. It is involved in olfaction and is adjacent to the amygdala. Undershoot The hyperpolarizing phase following an action potential where membrane potential temporarily becomes more negative than resting potential. Unilateral neglect A neuropsychological condition following damage (typically to the right parietal lobe) in which patients ignore stimuli on one side of space. Unipolar depression A mood disorder characterized by persistent low mood, lack of energy, and anhedonia, without manic episodes. Associated with altered activity in the prefrontal cortex and limbic structures. Unipolar neuron A type of neuron with a single process extending from the cell body. Common in invertebrates and found in human sensory neurons. Upper motor neuron A neuron originating in the cerebral cortex or brainstem that transmits motor signals to lower motor neurons. Damage leads to spasticity, hyperreflexia, and weakness.
Gambling in Singapore is controlled by several statutes, being the Casino Control Act, Gambling Control Act and Gambling Regulatory Authority of Singapore Act. The Gambling Regulatory Authority of Singapore (GRA) was formed on 1 August 2022, by reconstituting the Casino Regulatory Authority of Singapore (CRA), to regulate gambling in Singapore. It is a statutory board under the Ministry of Home Affairs. Singapore Pools is the only operator that is legally allowed to run lotteries in the country. Casinos are allowed in Singapore in the form of integrated resorts (IR), such as Marina Bay Sands and Resorts World Sentosa, where the casino is integrated in a major resort property that includes a hotel, together with convention facilities, entertainment shows, theme parks, luxury retail and fine dining. Societies are allowed to operate slot machines in designated rooms under the Gambling Control Act.
=== Peripheral edema and hypoalbuminemia === Kwashiorkor is a form of protein deficiency, which can result in both osmotic imbalances and irregularities in the lymphatic system. Kwashiorkor is most notable for peripheral edema. The presence of edema in kwashiorkor is correlated with very low albumin concentration (hypoalbuminemia). Edema results from a loss of fluid balance between the hydrostatic and oncotic pressures across the capillary blood vessel walls due to the lack of protein which affects the body's ability to draw fluid from the tissues into the bloodstream. Low albumin concentration influences negatively the strength of oncotic pressure. Failure leads to fluid buildup in the abdomen, resulting in edema and belly distension. Furthermore, the release of antidiuretic hormone is stimulated by hypovolemia, also leading to the development of peripheral edema. Plasma renin is also stimulated, promoting sodium retention. It is important to distinguish the pathophysiology of marasmus and kwashiorkor when it comes to treating malnourished children who may have hypovolemic shock that is caused by an acute loss of salt and water. Children with severe albumin deficiency struggle physiologically to maintain their blood volume.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.